MEBIAS, an emerging leader in the field of pathway-selective G-protein coupled receptor (GPCR) drug discovery, was founded in January 2016 by 3 highly experienced drug discovery scientists, formerly of Johnson & Johnson and Merck. Recently, many pharmaceutical firms have struggled with their internal drug pipelines and are increasingly relying on external collaborations. MEBIAS was founded to establish an alternative discovery model, offering a validated, rapid, and highly efficient drug discovery platform.
MEBIAS’ business model foresees partnering with select pharmaceutical firms on specific targets, as well as advancing its own molecules into early clinical development. One and a half years since its founding, the company has validated its unique drug discovery platform by identifying novel preclinical mu-opioid candidates, which in animal models exhibit efficacy similar to standard opioids while avoiding dangerous side effects.